Research graph
References from COMORBIDITY AND ITS IMPACT ON THE COURSE OF GOUT AND COVID-19. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/s41584-020-0441-1
10.1038/s41584-020-0441-1 · External reference
Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study
10.1136/annrheumdis-2013-204463 · 2015 · External reference
Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: A nationwide population-based study
10.1136/annrheumdis-2011-201254 · 2013 · External reference
Prevalence of Gout in the Adult Population of France
10.1002/acr.22660 · 2016 · External reference
Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008
10.1002/art.30520 · 2011 · External reference
Epidemiology and management of gout in Taiwan: A nationwide population study
10.1186/s13075-015-0522-8 · 2015 · External reference
The rising incidence of gout and the increasing burden of comorbidities: A population-based study over 20 years
10.3899/jrheum.170806 · 2018 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
A Systematic Review of the Economic and Humanistic Burden of Gout
10.1007/s40273-015-0288-5 · 2015 · External reference
Gout: a disease involved with complicated immunoinflammatory responses: a narrative review
10.1007/s10067-020-05090-8 · 2020 · External reference
Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout
10.1136/annrheumdis-2019-215521 · 2019 · External reference
Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey
10.1186/1477-7525-10-117 · 2012 · External reference
10.1016/j.amjmed.2011.09.033
10.1016/j.amjmed.2011.09.033 · External reference
10.1038/s41586-020-2521-4
10.1038/s41586-020-2521-4 · External reference
Crystal- proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study
10.1007/s10067-019-04520-6 · 2019 · External reference
10.1007/s00296-020-04764-5
10.1007/s00296-020-04764-5 · External reference
10.1016/s2665-9913(21)00073-4
10.1016/s2665-9913(21)00073-4 · External reference
2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
10.1136/annrheumdis-2015-208237 · 2015 · External reference
Unresolved reference
External reference
Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline
10.7326/0003-4819-158-11-201306040-00007 · 2013 · External reference
10.1016/j.jbspin.2017.05.010
10.1016/j.jbspin.2017.05.010 · External reference
10.1186/1477-7525-1-20
10.1186/1477-7525-1-20 · External reference
The PHQ-9: Validity of a brief depression severity measure
10.1046/j.1525-1497.2001.016009606.x · 2001 · External reference
Comorbidities in rheumatoid arthritis
10.1016/j.berh.2007.06.002 · 2007 · External reference
Content and construct validity of the Rheumatic Diseases Comorbidity Index in patients with gout
10.1093/rheumatology/kev030 · 2015 · External reference
2020 International society of hypertension global hypertension practice guidelines
10.1097/hjh.0000000000002453 · 2020 · External reference
2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
10.1093/eurheartj/ehz455 · 2020 · External reference
10.2337/dc21-s006
10.2337/dc21-s006 · External reference
Unresolved reference
External reference
Combined Use of Febuxostat and Colchicine Does Not Increase Acute Hepatotoxicity in Patients with Gout: A Retrospective Study
10.3390/jcm9051488 · 2020 · External reference
10.1080/14397595.2020.1784556
10.1080/14397595.2020.1784556 · External reference
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007- 2016
10.1002/art.40807 · 2019 · External reference
Inpatient management of gout in a New Zealand hospital: A retrospective audit
10.1111/1756-185x.12578 · 2016 · External reference
Target Serum Urate: Do Gout Patients Know Their Goal
10.1002/acr.22785 · 2016 · External reference
10.7759/cureus.13995
10.7759/cureus.13995 · External reference
Characteristics of and Important Lessons From the Coronavirus Disease 2019 ( COVID-19 ) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
10.1001/jama.2020.2648 · 2020 · External reference
10.1016/j.jbspin.2018.06.013
10.1016/j.jbspin.2018.06.013 · External reference
10.1093/rheumatology/key155
10.1093/rheumatology/key155 · External reference
Rate of adherence to urate-lowering therapy among patients with gout: A systematic review and meta-analysis
10.1136/bmjopen-2017-017542 · 2018 · External reference
Management of Gout in the United States: A Claims‐based Analysis
10.1002/acr2.11121 · 2020 · External reference
Gout in the UK and Germany: Prevalence, comorbidities and management in general practice 2000-2005
10.1136/ard.2007.076232 · 2008 · External reference
10.1016/j.jare.2017.04.008
10.1016/j.jare.2017.04.008 · External reference
10.1038/s41431-021-00830-z
10.1038/s41431-021-00830-z · External reference
10.1016/j.jbspin.2018.06.011
10.1016/j.jbspin.2018.06.011 · External reference
10.1007/s40744-020-00260-1
10.1007/s40744-020-00260-1 · External reference
10.1097/smj.0000000000000082
10.1097/smj.0000000000000082 · External reference
